title: Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach.
abstract: We report a case where targeted radionuclide therapy using 153Sm-EDTMP gave substantial palliative effect. A 35-year-old male with a primary osteosarcoma located in the first lumbar vertebra relapsed with progressive back pain after conventional treatment modalities had failed. He became bedridden, and developed paraparesis and impaired bladder function. On a diagnostic bone-scan intense radioactivity was localized in the tumor. He therefore was given 153Sm-EDTMP treatment twice, 8 weeks apart, 35 and 32 MBq/kg body weight respectively. After a few days the pain was significantly relieved and by the second radionuclide treatment the pareses subsided. For six months he was able to be up and about without any neurological signs or detectable metastases. Eventually, however, he experienced increasing local pain, developed paraparesis, was re-operated but died 4 months later. The dramatic transient improvement observed in this case warrants further exploration using 153Sm-EDTMP as a boost technique, supplementary to conventional external radiotherapy.
authors.affiliation: Department of Medical Oncology, The Norwegian Radium Hospital, Oslo, Norway.
authors.forename: O S
authors.initials: OS
authors.lastname: Bruland
authors.forename: A
authors.initials: A
authors.lastname: Skretting
authors.forename: O P
authors.initials: OP
authors.lastname: Solheim
authors.forename: M
authors.initials: M
authors.lastname: Aas
mesh_terms: D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000627:therapeutic use*; D001416:Back Pain / Q000209:etiology / Q000532:radiotherapy; D017809:Fatal Outcome; D006801:Humans; D008159:Lumbar Vertebrae / Q000528:radiation effects*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000150:complications / Q000532:radiotherapy*; D010148:Intractable Pain / Q000209:etiology / Q000532:radiotherapy; D010166:Palliative Care; D010291:Paresis / Q000209:etiology / Q000532:radiotherapy; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D012493:Samarium / Q000008:administration & dosage / Q000627:therapeutic use*; D013117:Spinal Cord Compression / Q000209:etiology / Q000532:radiotherapy; D013125:Spinal Neoplasms / Q000150:complications / Q000532:radiotherapy*; D001745:Urinary Bladder Diseases / Q000209:etiology
chemical_list: D018712:Analgesics, Non-Narcotic; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D012493:Samarium; C061972:samarium Sm-153 lexidronam